Publications by authors named "A M Bardelli"
The discovery of growth factors and their involvement in cancer represents the foundation of precision oncology. The preclinical and clinical development of agents targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) were accompanied by big hype and hopes, though the clinical testing of such agents clashed with intrinsic and acquired resistance, greatly limiting their therapeutic value. However, a better understanding of the biology of the EGFR signaling pathway in CRC, coupled with the development of liquid biopsy methodologies to study cancer evolution in real time, fostered the clinical refinement of anti-EGFR treatment in CRC.
View Article and Find Full Text PDFArticle Synopsis
- The study highlights the interest in PARP inhibitors for treating tumors with "BRCAness," particularly in colorectal cancers, as approximately 15% possess defects in the homologous recombination (HR) pathway, presenting new treatment opportunities.
- The researchers developed HRDirect, an advanced tool for predicting HR deficiency (HRD) in tumor samples, which outperformed existing assays by accurately identifying resistant colorectal cancer models.
- The study suggests a composite biomarker approach combining HRDirect scoring with ATM and RAD51C analysis to improve HRD tumor identification and enhance personalized treatment strategies for colorectal cancer patients.
Article Synopsis
- Liquid biopsy utilizing cell-free DNA (cfDNA) analysis shows potential for non-invasive cancer diagnosis and monitoring, but the mechanisms behind cfDNA release from tumors are not fully understood.
- A study on colorectal cancer cell lines revealed that increased cfDNA levels were linked to slower cell growth and more cell death, with less DNA methylation correlating to higher cfDNA shedding.
- Researchers developed a methylation signature to differentiate between high and low cfDNA releasers, which was validated on additional colorectal cancer cell lines and patient-derived organoids, demonstrating its predictive capability for cfDNA release.
Background: We studied the poorly-known dynamics of circulating DNA (cir-nDNA), as monitored prospectively over an extended post-surgery period, in patients with cancer.
Methods: On patients with stage III colon cancer (N = 120), using personalised molecular tags we carried out the prospective, multicenter, blinded cohort study of the post-surgery serial analysis of cir-nDNA concentration. 74 patients were included and 357 plasma samples tested.
Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. Chemotherapy continues to serve as the primary treatment modality, while immunotherapy is largely ineffective for the majority of CRC patients. Seminal discoveries have emphasized that modifying DNA damage response (DDR) mechanisms confers both cell-autonomous and immune-related vulnerabilities across various cancers.
View Article and Find Full Text PDF